Sort   by:  
 Page size 
UnknownStructural determinants of allosteric antagonism at metabotropic glutamate receptor 2: mechanistic studies with new potent negative allosteric modulators.
Not available
S-EPMC3188907 | biostudies-literature
UnknownLack of Blue Light Regulation of Antioxidants and Chilling Tolerance in Basil.
Not available
S-EPMC9021895 | biostudies-literature
UnknownDevelopmental dynamics between reading and math in elementary school.
Not available
S-EPMC7725923 | biostudies-literature
UnknownEffect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study.
Not available
S-EPMC4171746 | biostudies-literature
UnknownImpact of Certolizumab Pegol on Patient-Reported Outcomes in Patients With Axial Spondyloarthritis.
Not available
S-EPMC5054930 | biostudies-literature
UnknownMesoproterozoic surface oxygenation accompanied major sedimentary manganese deposition at 1.4 and 1.1 Ga.
Not available
S-EPMC10087800 | biostudies-literature
UnknownEffect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol.
Not available
S-EPMC3888591 | biostudies-literature
UnknownPotential of DNA methylation in rectal cancer as diagnostic and prognostic biomarkers.
Not available
S-EPMC4651135 | biostudies-literature
UnknownEffect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA).
Not available
S-EPMC3888622 | biostudies-literature
UnknownPhase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.
Not available
S-EPMC7479959 | biostudies-literature
Sort   by:  
 Page size